Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium-Reference-Cited by-同舟云学术

Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium

Published:2023-03 Issue:3 Volume:18 Page:313-323
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

García-Pardo Miguel^ORCID,Chang Amy,Schmid Sabine,Dong Mei,Brown M. Catherine,Christiani David,Tindel Hilary Aurora,Brennan Paul,Chen Chu,Zhang Jie,Ryan Brid M.,Zaridze David,Schabath Matthew B.,Leal Leticia Ferro,Reis Rui Manuel,Tardon Adonina,Fernández-Tardon Guillermo,Shete Sanjay S.,Andrew Angeline,Brenner Hermann,Xu Wei,Hung Rayjean J.,Liu Geoffrey

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020

3. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater;Reck;J Clin Oncol,2019

4. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer;Peters;N Engl J Med,2017

5. Annual report to the nation on the status of cancer, featuring cancer in men and women age 20–49 years;Ward;J Natl Cancer Inst,2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Are comorbidities associated with differences in healthcare charges among lung cancer patients in US hospitals? Focusing on variances by patient and socioeconomic factors;Chronic Illness;2024-03-27

2. Sub-lobar resections for peripheral non-small cell lung cancer measuring ≤ 2 cm: Insights from recent clinical trials;Radiotherapy and Oncology;2024-03

3. IPSOS trial: A “game changer” redefining first-line immunotherapy in platinum-ineligible NSCLC;Med;2023-11

4. Comment on “Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium”;Journal of Thoracic Oncology;2023-09

5. An Individualized Approach to Comorbidities in Lung Cancer;Journal of Thoracic Oncology;2023-03